Dysregulation of the Tau-Microtubule-End-Binding Protein Axis in Alzheimer's Disease and Related Tauopathies.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical and mechanistic literature without systematic methodology or primary human data.
PubMed 42353182 · doi:10.3390/ijms27125467
What was done
This narrative review synthesized recent research regarding the interaction between the microtubule-associated protein tau and the end-binding protein (EBP) family—specifically EB1 and EB3—in regulating microtubule dynamics, stability, and neurodegenerative pathology in Alzheimer's disease and related tauopathies.
What was found
The abstract reports no quantitative metrics or numerical findings. It notes qualitatively that pathological tau impairs EB3 localization to microtubule plus-ends, inhibiting EB3-driven microtubule elongation and stability. Furthermore, in vitro evidence indicates that EB1 can interfere with tau aggregation in biomolecular condensates, suggesting that disruption of the tau-microtubule-EBP network contributes to structural and functional microtubule instability.
Why it matters
Broadening focus from isolated tau hyperphosphorylation to the broader network of microtubule-associated plus-end-tracking proteins reveals novel mechanistic pathways of cytoskeletal collapse in tauopathies, presenting alternative targets for therapeutic intervention.
Limits
As a narrative review, it presents no original empirical data, quantitative synthesis, or systematic search methodology. The underlying findings primarily rely on in vitro and cell-free mechanistic models that may not accurately replicate complex in vivo human neurobiology.
Cited by
- supports Tau hyperphosphorylation causes tau to dissociate from microtubules, leading to structural microtubule and synaptic collapse.